Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | YAP1 | P46937 | 1/20 | 0.42 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418823 | 0.82 | KCNK3 (0.70) | HTTLMNAKCNK3POLBALDH1A1 | |
| SCHEMBL5531122 | 0.76 | SMN1; SMN2 (0.43) | HTTALDH1A1CYP2C19 | |
| SCHEMBL20634019 | 0.75 | HPGD (0.55) | HTTHPGDLMNAPOLBALDH1A1 | |
| SCHEMBL11270164 | 0.75 | HPGD (0.55) | HTTHPGDLMNAPOLBALDH1A1 | |
| SCHEMBL4742813 | 0.75 | ALDH1A1 (0.60) | HTTHPGDPOLBALDH1A1CYP2C9 | |
| Hydrochloric Acid SCHEMBL28148044 | 0.75 | CYP3A4 (0.51) | HTTLMNAKCNK3POLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL28148043 | 0.75 | CYP3A4 (0.51) | HTTLMNAKCNK3POLBALDH1A1 | |
| SCHEMBL5898651 | 0.74 | SMN1; SMN2 (0.42) | HTTALDH1A1CYP2C19 | |
| SCHEMBL28148077 | 0.74 | KCNK3 (0.42) | HTTLMNAKCNK3POLBCYP3A4 | |
| SCHEMBL10396678 | 0.73 | MEN1 (0.41) | ALDH1A1KMT2ACYP2C9CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010084516-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE N-ALKYL-PIPERIDINE-2-CARBOXANILIDE | JUBILANT ORGANOSYS LIMITED (IN) | 2010-07-29 | — | — | WO | claimed |
| CN-102093284-B | Method for enriching piperidine-2-formanilide optically active compound | YICHANG HUMANWELL PHARMACEUTICAL CO LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-102093284-A | Method for enriching piperidine-2-formanilide optically active compound | YICHANG HUMANWELL PHARMACEUTICAL CO LTD | 2011-06-15 | — | — | CN | disclosed |
| WO-2010084516-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE N-ALKYL-PIPERIDINE-2-CARBOXANILIDE | JUBILANT ORGANOSYS LIMITED (IN) | 2010-07-29 | — | — | WO | disclosed |
| CN-1172912-C | Racemisation process for use in manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents | ��������ķ������ | 2004-10-27 | — | — | CN | disclosed |
| EP-0804417-B1 | RACEMISATION PROCESS FOR USE IN THE MANUFACTURE OF LEVOBUPIVACAINE AND RELATED PIPERIDINECARBOXANILIDE ANAESTHETIC AGENTS | DARWIN DISCOVERY LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-6384227-B2 | HEATING THE COMPOUND IN AN AQUEOUS MEDIUM WHICH INCLUDES AN ORGANIC COSOLVENT, AND RECOVERING THE PRODUCT THAT IS PRECIPITATED, ON COOLING | DARWIN DISCOVERY LTD. (GB) | 2002-05-07 | — | — | US | disclosed |
| US-20010000522-A1 | Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents | DYER ULRICH CONRAD (GB) | 2001-04-26 | — | — | US | disclosed |
| CN-1168134-A | Racemization process for the production of levobupivacaine and related piperidinecarboxanilide anaesthetics | CHIROSCIENCE LTD (GB) | 1997-12-17 | — | — | CN | disclosed |
| EP-0804417-A1 | RACEMISATION PROCESS FOR USE IN THE MANUFACTURE OF LEVOBUPIVACAINE AND RELATED PIPERIDINECARBOXANILIDE ANAESTHETIC AGENTS | Chiroscience Limited (GB) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022281-A1 | RACEMISATION PROCESS FOR USE IN THE MANUFACTURE OF LEVOBUPIVACAINE AND RELATED PIPERIDINECARBOXANILIDE ANAESTHETIC AGENTS | CHIROSCIENCE LIMITED (GB) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000522-A1 | Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents | OPRM1, OPRD1, CYP2C9 | HTT 2526/4885HPGD 1245/4885LMNA 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.